Cancer Advisor

Introduction: A New Era in Cancer Care Cancer treatment is evolving faster than ever. From cutting-edge immunotherapies to AI-driven diagnostics, the discoveries of 2025–2026 are reshaping how clinicians detect, monitor, and treat malignancies. These breakthroughs offer hope for longer survival, improved quality of life, and personalized therapies tailored to each patient. Credit:  Statista 1. Immunotherapy: Expanding Beyond Checkpoints Immune checkpoint inhibitors (like pembrolizumab and nivolumab) remain foundational, while CAR‑T therapies, bispecific antibodies, and tumor-infiltrating lymphocytes (TILs) expand treatment options for previously resistant solid tumors. Key Highlights: CAR‑T therapy demonstrates survival benefits in advanced gastric and gastroesophageal junction cancers — a first for solid tumors. Bispecific and dual checkpoint agents provide deeper, more durable responses in early trials. Note: These therapies carry potential risks, including cytokine release syn...

Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...